
Global Epigenomics Market Size study, by Product Type (Reagents, Kits, Enzymes, Others), by Technology (DNA Methylation, Histone Methylation, Histone Acetylation, MicroRNA Modification, Large Non-coding RNA, Chromatin Structures, Others), by Application (
Description
The Global Epigenomics Market was valued at approximately USD 2.13 billion in 2024 and is anticipated to grow with a healthy growth rateof 15.5% over the forecast period 2024-2034. Epigenomics is the study of the complete set of epigenetic modifications on the genetic material of a cell, which can influence gene expression without altering the underlying DNA sequence. These modifications, such as DNA methylation and histone modification, affect how genes are turned on or off, and can be inherited or influenced by environmental factors. By examining these changes across the entire genome, epigenomics seeks to understand how these regulatory mechanisms contribute to development, disease, and variation among individuals. This field provides insights into gene regulation and potential therapeutic targets for various conditions.
The increasing research in epigenetics and the rising incidence of chronic diseases are key drivers enhancing market growth. This burgeoning field has captivated researchers, clinicians, and industry leaders, driven by the potential to unravel the intricate mechanisms of gene expression regulation. This surge in research is fueled by the promise of identifying epigenetic markers that can facilitate early disease detection, prognostic assessments, and therapeutic stratification, especially for complex diseases like cancer, neurological disorders, and cardiovascular conditions. Furthermore, the growing awareness and understanding of epigenomics within the scientific community and the general public have spurred interest and investment in the field. Public and private funding for epigenomics research has surged, providing researchers with the resources necessary to delve deeper into the intricacies of epigenetic regulation. This heightened interest, coupled with substantial investments, is propelling the growth of the epigenomics market.
The key region in the Global Epigenomics Market includes North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2024, North America dominated the Epigenomics Market in terms of revenue due to a combination of advanced research infrastructure, high investment in biotechnology, and robust funding for scientific research. The region's leading academic and research institutions drive innovation in epigenomics, facilitating the development of new technologies and therapeutic approaches. In addition, North American countries benefit from a well-established network of biotechnology companies and strong support from government and private sector funding, further bolstering market growth. The presence of key players in the industry and increasing collaborations between research institutions and biotech firms also contribute to the region's leadership in the epigenomics field. Furthermore, Asia Pacific expected fastest CAGR growth during the forecast period 2024-2034.
Key players in the market include:
Novartis AG
Abbott Laboratories
Illumina Inc.
Abcam plc
Merck KGaA
Thermo Fisher Scientific Inc.
Zymo Research Corporation
Agilent Technologies Inc.
Epizyme Inc.
Boehringer Ingelheim International GmbH
Bayer AG
The detailed segments and sub-segments of the market are explained below:
By Product Type:
Reagents
Kits
Enzymes
Others
By Technology:
DNA Methylation
Histone Methylation
Histone Acetylation
MicroRNA Modification
Large Non-coding RNA
Chromatin Structures
Others
By Application:
Pharmaceutical
Diagnostics
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year – 2022
Base year – 2024
Forecast period – 2024 to 2034
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2034.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.
The increasing research in epigenetics and the rising incidence of chronic diseases are key drivers enhancing market growth. This burgeoning field has captivated researchers, clinicians, and industry leaders, driven by the potential to unravel the intricate mechanisms of gene expression regulation. This surge in research is fueled by the promise of identifying epigenetic markers that can facilitate early disease detection, prognostic assessments, and therapeutic stratification, especially for complex diseases like cancer, neurological disorders, and cardiovascular conditions. Furthermore, the growing awareness and understanding of epigenomics within the scientific community and the general public have spurred interest and investment in the field. Public and private funding for epigenomics research has surged, providing researchers with the resources necessary to delve deeper into the intricacies of epigenetic regulation. This heightened interest, coupled with substantial investments, is propelling the growth of the epigenomics market.
The key region in the Global Epigenomics Market includes North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2024, North America dominated the Epigenomics Market in terms of revenue due to a combination of advanced research infrastructure, high investment in biotechnology, and robust funding for scientific research. The region's leading academic and research institutions drive innovation in epigenomics, facilitating the development of new technologies and therapeutic approaches. In addition, North American countries benefit from a well-established network of biotechnology companies and strong support from government and private sector funding, further bolstering market growth. The presence of key players in the industry and increasing collaborations between research institutions and biotech firms also contribute to the region's leadership in the epigenomics field. Furthermore, Asia Pacific expected fastest CAGR growth during the forecast period 2024-2034.
Key players in the market include:
Novartis AG
Abbott Laboratories
Illumina Inc.
Abcam plc
Merck KGaA
Thermo Fisher Scientific Inc.
Zymo Research Corporation
Agilent Technologies Inc.
Epizyme Inc.
Boehringer Ingelheim International GmbH
Bayer AG
The detailed segments and sub-segments of the market are explained below:
By Product Type:
Reagents
Kits
Enzymes
Others
By Technology:
DNA Methylation
Histone Methylation
Histone Acetylation
MicroRNA Modification
Large Non-coding RNA
Chromatin Structures
Others
By Application:
Pharmaceutical
Diagnostics
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year – 2022
Base year – 2024
Forecast period – 2024 to 2034
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2034.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.
Table of Contents
285 Pages
- Chapter 1. Global Epigenomics Market Executive Summary
- 1.1. Global Epigenomics Market Size & Forecast (2024-2034)
- 1.2. Regional Summary
- 1.3. Segmental Summary
- 1.3.1. By Product Type
- 1.3.2. By Technology
- 1.3.3. By Application
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6 Investment Analysis
- 1.7 Investment Rationale
- 1.8 Key Industry Metrics
- 1.9. Analyst Recommendation & Conclusion1.6 Investment Analysis
- 1.7 Investment Rationale
- 1.8 Key Industry Metrics
- 1.9. Analyst Recommendation & Conclusion
- Chapter 2. Global Epigenomics Market Definition and Research Assumptions
- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
- 2.3.3.1. Availability
- 2.3.3.2. Infrastructure
- 2.3.3.3. Regulatory Environment
- 2.3.3.4. Market Competition
- 2.3.3.5. Economic Viability (Consumer’s Perspective)
- 2.3.4. Demand Side Analysis
- 2.3.4.1. Regulatory frameworks
- 2.3.4.2. Technological Advancements
- 2.3.4.3. Environmental Considerations
- 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates
- Chapter 3. Global Epigenomics Market Dynamics
- 3.1. Market Drivers
- 3.1.1. Increasing Research in Epigenetics
- 3.1.2. Rising Incidence of Chronic Diseases
- 3.1.3. Advancements in Epigenetic Technologies
- 3.2. Market Challenges
- 3.2.1. High Cost of Epigenetic Research
- 3.2.2. Complexity of Epigenetic Mechanisms
- 3.3. Market Opportunities
- 3.3.1. Personalized Medicine Advancements
- 3.3.2. Interdisciplinary Collaborations
- 3.3.3. Public and Private Funding Increases
- Chapter 4. Global Epigenomics Market Industry Analysis
- 4.1. Porter’s 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter’s 5 Force Model
- 4.1.7. Porter’s 5 Force Impact Analysis
- 4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
- 4.3. Top investment opportunity
- 4.4. Top winning strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion
- Chapter 5. Global Epigenomics Market Size & Forecasts by Product Type 2024-2034
- 5.1. Segment Dashboard
- 5.2. Global Epigenomics Market: Product Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Reagents
- 5.2.2. Kits
- 5.2.3. Enzymes
- 5.2.4. Others
- Chapter 6. Global Epigenomics Market Size & Forecasts by Technology 2024-2034
- 6.1. Segment Dashboard
- 6.2. Global Epigenomics Market: Technology Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. DNA Methylation
- 6.2.2. Histone Methylation
- 6.2.3. Histone Acetylation
- 6.2.4. MicroRNA Modification
- 6.2.5. Large Non-coding RNA
- 6.2.6. Chromatin Structures
- 6.2.7. Others
- Chapter 7. Global Epigenomics Market Size & Forecasts by Application 2024-2034
- 7.1. Segment Dashboard
- 7.2. Global Epigenomics Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Pharmaceutical
- 7.2.2. Diagnostics
- Chapter 8. Global Epigenomics Market Size & Forecasts by Region 2024-2034
- 8.1. North America Epigenomics Market
- 8.1.1. U.S. Epigenomics Market
- 8.1.1.1. Product Type breakdown size & forecasts, 2024-2034
- 8.1.1.2. Technology breakdown size & forecasts, 2024-2034
- 8.1.1.3. Application breakdown size & forecasts, 2024-2034
- 8.1.2. Canada Epigenomics Market
- 8.1.2.1. Product Type breakdown size & forecasts, 2024-2034
- 8.1.2.2. Technology breakdown size & forecasts, 2024-2034
- 8.1.2.3. Application breakdown size & forecasts, 2024-2034
- 8.2. Europe Epigenomics Market
- 8.2.1. U.K. Epigenomics Market
- 8.2.1.1. Product Type breakdown size & forecasts, 2024-2034
- 8.2.1.2. Technology breakdown size & forecasts, 2024-2034
- 8.2.1.3. Application breakdown size & forecasts, 2024-2034
- 8.2.2. Germany Epigenomics Market
- 8.2.2.1. Product Type breakdown size & forecasts, 2024-2034
- 8.2.2.2. Technology breakdown size & forecasts, 2024-2034
- 8.2.2.3. Application breakdown size & forecasts, 2024-2034
- 8.2.3. France Epigenomics Market
- 8.2.3.1. Product Type breakdown size & forecasts, 2024-2034
- 8.2.3.2. Technology breakdown size & forecasts, 2024-2034
- 8.2.3.3. Application breakdown size & forecasts, 2024-2034
- 8.2.4. Spain Epigenomics Market
- 8.2.4.1. Product Type breakdown size & forecasts, 2024-2034
- 8.2.4.2. Technology breakdown size & forecasts, 2024-2034
- 8.2.4.3. Application breakdown size & forecasts, 2024-2034
- 8.2.5. Italy Epigenomics Market
- 8.2.5.1. Product Type breakdown size & forecasts, 2024-2034
- 8.2.5.2. Technology breakdown size & forecasts, 2024-2034
- 8.2.5.3. Application breakdown size & forecasts, 2024-2034
- 8.2.6. Rest of Europe Epigenomics Market
- 8.2.6.1. Product Type breakdown size & forecasts, 2024-2034
- 8.2.6.2. Technology breakdown size & forecasts, 2024-2034
- 8.2.6.3. Application breakdown size & forecasts, 2024-2034
- 8.3. Asia-Pacific Epigenomics Market
- 8.3.1. China Epigenomics Market
- 8.3.1.1. Product Type breakdown size & forecasts, 2024-2034
- 8.3.1.2. Technology breakdown size & forecasts, 2024-2034
- 8.3.1.3. Application breakdown size & forecasts, 2024-2034
- 8.3.2. India Epigenomics Market
- 8.3.2.1. Product Type breakdown size & forecasts, 2024-2034
- 8.3.2.2. Technology breakdown size & forecasts, 2024-2034
- 8.3.2.3. Application breakdown size & forecasts, 2024-2034
- 8.3.3. Japan Epigenomics Market
- 8.3.3.1. Product Type breakdown size & forecasts, 2024-2034
- 8.3.3.2. Technology breakdown size & forecasts, 2024-2034
- 8.3.3.3. Application breakdown size & forecasts, 2024-2034
- 8.3.4. Australia Epigenomics Market
- 8.3.4.1. Product Type breakdown size & forecasts, 2024-2034
- 8.3.4.2. Technology breakdown size & forecasts, 2024-2034
- 8.3.4.3. Application breakdown size & forecasts, 2024-2034
- 8.3.5. South Korea Epigenomics Market
- 8.3.5.1. Product Type breakdown size & forecasts, 2024-2034
- 8.3.5.2. Technology breakdown size & forecasts, 2024-2034
- 8.3.5.3. Application breakdown size & forecasts, 2024-2034
- 8.3.6. Rest of Asia Pacific Epigenomics Market
- 8.3.6.1. Product Type breakdown size & forecasts, 2024-2034
- 8.3.6.2. Technology breakdown size & forecasts, 2024-2034
- 8.3.6.3. Application breakdown size & forecasts, 2024-2034
- 8.4. Latin America Epigenomics Market
- 8.4.1. Brazil Epigenomics Market
- 8.4.1.1. Product Type breakdown size & forecasts, 2024-2034
- 8.4.1.2. Technology breakdown size & forecasts, 2024-2034
- 8.4.1.3. Application breakdown size & forecasts, 2024-2034
- 8.4.2. Mexico Epigenomics Market
- 8.4.2.1. Product Type breakdown size & forecasts, 2024-2034
- 8.4.2.2. Technology breakdown size & forecasts, 2024-2034
- 8.4.2.3. Application breakdown size & forecasts, 2024-2034
- 8.4.3. Rest of Latin America Epigenomics Market
- 8.4.3.1. Product Type breakdown size & forecasts, 2024-2034
- 8.4.3.2. Technology breakdown size & forecasts, 2024-2034
- 8.4.3.3. Application breakdown size & forecasts, 2024-2034
- 8.5. Middle East & Africa Epigenomics Market
- 8.5.1. Saudi Arabia Epigenomics Market
- 8.5.1.1. Product Type breakdown size & forecasts, 2024-2034
- 8.5.1.2. Technology breakdown size & forecasts, 2024-2034
- 8.5.1.3. Application breakdown size & forecasts, 2024-2034
- 8.5.2. South Africa Epigenomics Market
- 8.5.2.1. Product Type breakdown size & forecasts, 2024-2034
- 8.5.2.2. Technology breakdown size & forecasts, 2024-2034
- 8.5.2.3. Application breakdown size & forecasts, 2024-2034
- 8.5.3. Rest of Middle East & Africa Epigenomics Market
- 8.5.3.1. Product Type breakdown size & forecasts, 2024-2034
- 8.5.3.2. Technology breakdown size & forecasts, 2024-2034
- 8.5.3.3. Application breakdown size & forecasts, 2024-2034
- Chapter 9. Competitive Intelligence
- 9.1. Key Company SWOT Analysis
- 9.1.1. Company 1
- 9.1.2. Company 2
- 9.1.3. Company 3
- 9.2. Top Market Strategies
- 9.3. Company Profiles
- 9.3.1. Novartis AG
- 9.3.1.1. Key Information
- 9.3.1.2. Overview
- 9.3.1.3. Financial (Subject to Data Availability)
- 9.3.1.4. Product Summary
- 9.3.1.5. Market Strategies
- 9.3.2. Abbott Laboratories
- 9.3.3. Abcam plc
- 9.3.4. Zymo Research Corporation
- 9.3.5. Agilent Technologies Inc.
- 9.3.6. Epizyme Inc.
- 9.3.7. Boehringer Ingelheim International GmbH
- 9.3.8. Bayer AG
- 9.3.9. Thermo Fisher Scientific Inc.
- 9.3.10. Illumina Inc.
- 9.3.11. Merck KGaA
- Chapter 10. Research Process
- 10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
- 10.2. Research Attributes
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.